This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SABCS 2023
Presentations
Seagen Development Pipeline
Session Info Card
Tucatinib | Breast Cancer | Abstract #1544187
HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer
Tucatinib | Breast Cancer | Abstract #1573051
Trial in progress: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05)
Disitamab Vedotin & Tucatinib | Abstract #1577368
Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models